Tomasz Kamil Kucharczyk

Dr. Tomasz Kamil Kucharczyk

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 March 2014 in Medical Oncology
Verified
Journal Article
Open access
PDF file
TPTomasz Powrózek
Tomasz Powrózek
PKPawel Krawczyk
Pawel Krawczyk
TKTomasz Kamil Kucharczyk
Tomasz Kamil Kucharczyk
JMJanusz Milanowski
Janusz Milanowski
Currently, there are no sensitive diagnostic tests that could allow early detection of lung cancer. Among some cancer patients, epigenetic changes in the nature of methylation of different gene promoter regions are observed, which affect expression of suppressor genes such as septin 9 (SEPT9). Due to the ability of detecting these changes in free circulating DNA in peripheral blood, such genes may become ideal markers in early and noninvasive diagnostics of cancer. Methylation of SEPT9 promoter region in plasma DNA is observed frequently in colorectal cancer patients. The aim of the study was to define the frequency of SEPT9 promoter methylation in lung cancer patients and evaluation of usefulness of this marker in early diagnostic of lung cancer. Plasma samples were obtained from 70 untreated patients with different lung cancer pathological diagnosis and disease stage and from 100 healthy individuals. DNA was isolated from peripheral blood plasma and was then subjected to bisulfitation, purification and elution using Abbott mSEPT9 Detection Kit. Methylation level was assessed by real-time PCR with the use of specific SEPT9 promoter methylation probe. Each sample was assayed in the presence of positive and negative control. SEPT9 promoter methylation was detected in 31 (44.3 % of the whole studied group) of lung cancer patients finding the result positive when methylation was detected in 1 out of 3 repetitions of each test sample determinations. The marker was present in patients with different pathological diagnosis and disease stage. Analysis of SEPT9 promoter region methylation may be useful in early diagnosis of lung cancer.

16 July 2014 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Open access
PDF file
PKPawel Krawczyk
Pawel Krawczyk
TKTomasz Kamil Kucharczyk
Tomasz Kamil Kucharczyk
DKDariusz M. Kowalski
Dariusz M. Kowalski
TPTomasz Powrózek
Tomasz Powrózek
RRRodryg Ramlau
Rodryg Ramlau
JMJanusz Milanowski
Janusz Milanowski
We presented retrospective analysis of up to five polymorphisms in TS, MTHFR and ERCC1 genes as molecular predictive markers for homogeneous Caucasian, non-squamous NSCLC patients treated with pemetrexed and platinum front-line chemotherapy.

26 August 2013 in Oncology Reports
Verified
Journal Article
Open access
PDF file
Radosław MlakRadosław Mlak
Radosław Mlak
PKPawel Krawczyk
Pawel Krawczyk
RRRodryg Ramlau
Rodryg Ramlau
EKEwa Kalinka
Ewa Kalinka
MWMaja Wasylecka-Morawiec
Maja Wasylecka-Morawiec
JMJanusz Milanowski
Janusz Milanowski
Platinum-based chemotherapy with third generation drugs (such as gemcitabine) is an efficacious regimen of first-line treatment of patients with advanced, unresectable non-small cell lung cancer (NSCLC), without activating EGFR mutations. Mechanism of action of cytostatics are distortions in the DNA. ERCC1 and RRM1 are key proteins involved in the repair of DNA, thus, they may be responsible for the ineffectiveness of therapy. We investigated whether ERCC1 (19007C>T) and RRM1 (-37C>A) polymorphisms impact response to chemotherapy and survival in 62 patients with NSCLC treated with platinum and gemcitabine. Single nucleotide polymorphisms (SNPs) were assessed using a PCR-RFLP method in DNA isolated from PBLs. There were no statistically significant relationships between ERCC1 genotypes and response to therapy (p=0.581, χ2=1.09) as well as patient overall survival (OS). Carriers of the RRM1 AC genotype showed disease progression significantly more frequently (p=0.019, χ2=5.473) compared to carriers of the AA or CC genotypes. Carriers of the ERCC1/RRM1TT/CC genotype combination showed disease control significantly more frequently (p=0.047, χ2=3.95) compared to carriers of other genotype combinations. Patients with AA or CC genotypes of RRM1 showed significantly higher progression-free survival probability (p=0.0001, HR=0.39, 95% CI, 0.22-0.70) and OS probability (p=0.0104, HR=0.39, 95% CI, 0.18-0.82) compared to those with the AC genotype. In Cox regression model, poor performance status (p=0.0016, HR=4.78, 95% CI, 1.82-12.56), AC genotype of RRM1 gene (p=0.0414, HR=2.47, 95% CI, 1.04-5.87), lack of prior surgical treatment (p=0.0425, HR=4.71, 95% CI, 1.06-20.92) and lack of subsequent lines of treatment (p=0.0127, HR=3.23, 95% CI, 1.29-8.11) were significantly associated with shortening of patient survival. The analysis of RRM1 (-37C>A) more than ERCC1 (19007C>T) polymorphism may be a promising tool in the qualification of NSCLC patients for chemotherapy containing platinum compounds and gemcitabine.

19 December 2019 in Annals of Agricultural and Environmental Medicine
Verified
Journal Article
Open access
BMBarbara Mackiewicz
Barbara Mackiewicz
JDJacek Dutkiewicz
Jacek Dutkiewicz
JSJan Siwiec
Jan Siwiec
TKTomasz Kamil Kucharczyk
Tomasz Kamil Kucharczyk
ESElżbieta Siek
Elżbieta Siek
Janusz MilanowskiJanusz Milanowski
Janusz Milanowski
Case description: Five workers (2 males and 3 females) employed in a furniture factory located in eastern Poland developed hypersensitivity pneumonitis (HP) after the pine wood used for furniture production was replaced by birch wood. All of them reported onset of respiratory and general...

18 October 2022 in Cells
Verified
Journal Article
Open access
PDF file
NKNatalia Krzyżanowska
Natalia Krzyżanowska
PKPawel Krawczyk
Pawel Krawczyk
KWKamila Wojas
Kamila Wojas
TKTomasz Kamil Kucharczyk
Tomasz Kamil Kucharczyk
Janusz MilanowskiJanusz Milanowski
Janusz Milanowski
For many years, researchers have been trying to develop the most effective ways to fight lung cancer, which is the cause of the largest number of cancer-related deaths among men and women worldwide. The most advanced treatments for nearly all non-small-cell lung cancer (NSCLC) types include immunotherapy with immune checkpoint inhibitors (ICIs), mainly anti-programmed death 1/anti-programmed death ligand 1 monoclonal antibodies (anti-PD-1/PD-L1 mAbs) in monotherapy or in combination with other strategies. Despite significant advances, long survival is not achievable in most cases, so new solutions are constantly being sought. One of the questions raised by oncologists is the efficacy of ICIs in patients with molecular driver alterations, especially when the possibilities of using molecularly targeted therapies are exhausted (e.g., due to resistance to tyrosine kinase inhibitors). There are studies investigating this problem, but it is still poorly described. Among probable immunotherapy’ failures reasons, low immunogenicity of tumors with one driver mutation is listed. Nevertheless, in some cases, the therapy is efficient, and more research is required to establish the management of NSCLC patients with oncogenic driver abnormalities. The aim of this article is to review current discoveries in this matter.

27 February 2014 in Asia-Pacific Journal of Clinical Oncology
Verified
Journal Article
Closed access
PDF file
TPTomasz Powrózek
Tomasz Powrózek
PKPawel Krawczyk
Pawel Krawczyk
RRRodryg Ramlau
Rodryg Ramlau
SSSylwia Sura
Sylwia Sura
KWKamila Wojas
Kamila Wojas
JMJanusz Milanowski
Janusz Milanowski